Overview

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

To compare the efficacy of the combination of lenalidomide with low-dose melphalan versus high-dose melphalan in newly diagnosed, symptomatic MM patients.

Phase:

Phase 3

Details

Lead Sponsor:

Fondazione EMN Italy Onlus
Fondazione Neoplasie Sangue Onlus

Treatments:

Lenalidomide
Melphalan
Prednisone
Thalidomide